Biotechnology

Mustang Bio completed construction of its 27,000-sf cell therapy manufacturing center in November of 2018. Located in the UMass Medicine Science Park in Worcester, the facility supports the clinical development and commercialization of Mustang's CAR-T and gene therapy product candidates. Accommodating proprietary cell therapy research, the project involved the renovation of labs and offices, as well as the conversion of existing labs to create three cGMP ISO7 clinical production areas.

AbbVie signed a long-term lease in November of 2018 for 480,000 sf in the Gateway of Pacific development in South San Francisco. The facility will be located in a 12-story building currently being constructed by BioMed Realty. Gateway of Pacific is being delivered in two phases, with the first phase comprising 555,000 sf of lab, research, office, and amenity space. Completion is expected in late 2019. The second phase will provide an additional 431,000 sf of lab, office, and parking space and is slated for completion in late 2021.

LA BioMed is planning to build a $63 million bioscience research facility on its existing campus in Torrance, Calif. The four-story building will include an 18,000-sf business incubator able to accommodate up to 30 companies at full capacity. The project will support the translation of research discoveries into innovative solutions and products. Occupancy is expected in February of 2019. 

The United Kingdom's Medical Research Council is planning to build the £75 million London Institute of Medical Sciences. Designed by Hawkins\Brown, the 110,000-sf project will provide collaborative biomedical research facilities including two CL-2 biocontainment labs, vibration-mitigated imaging suites, core biotechnology labs, write-up areas, and a data center. The nine-story facility is being created in partnership with Imperial College London and will accommodate up to 45 research groups currently dispersed around Hammersmith Hospital.

Atara Biotherapeutics opened a $55 million manufacturing facility in June of 2018 in Thousand Oaks, Calif. Designed by HPA Architects to meet LEED sustainable design criteria, the Atara T-cell Operations and Manufacturing (ATOM) center houses a 90,000-sf facility for the production of CAR-T allogeneic therapies, as well as additional R&D labs and offices. The project was developed by Sares-Regis Group with Atara signing a 15-year lease for the building.

Valent Biosciences opened the 85,000-sf Biorational Research Center in July of 2018 in Libertyville, Ill. Sited adjacent to the company's existing headquarters, the facility offers 65,000 sf of open lab space designed to foster collaborative research and development. The facility features a state-of-the-art 20,000-sf greenhouse to support the creation of innovative agricultural products and technologies. Valent Biosciences is a subsidiary of Sumitomo Chemical Company Health and Crop Sciences. 

Pfizer is planning to construct a 400,000-sf modular aseptic processing facility on its existing campus in Portage, Mich. Part of a $1.1 billion investment in Kalamazoo County over the next six years, the $465 million center will be one of the world’s most advanced facilities for the manufacture of sterile injectables.

16 Tech Community Corporation will break ground in fall of 2018 on the $30 million Advanced Research and Innovation Facility in Indianapolis. The Indiana Biosciences Research Institute will lease space in the five-story, 120,000-sf building, which represents the first phase of construction in the 16 Tech Innovation District. The 60-acre development will include a second office and research building, a 250-unit apartment complex, and renovated warehouse facilities.

Thomas Jefferson University is planning to create the Jefferson Institute for Bioprocessing in Lower Gwynedd, Pa. Located at Spring House Innovation Park, the 25,000-sf facility is being developed in partnership with the National Institute for Bioprocessing Research and Training (NIBRT) based in Dublin, Ireland. As the only center of its kind in North America, the project will leverage the renowned NIBRT curriculum to deliver state-of-the-art education and training programs in biopharmaceutical processing to approximately 2,500 people annually.

AstraZeneca opened its 163,000-sf South San Francisco facility in May of 2018. Located in the Cove at Oyster Point, the project houses a total of 400 employees from four organizations: Acerta Pharma, MedImmune, Pearl Therapeutics, and Technology Innovation & Delivery Excellence (TIDE). Designed by HOK to promote collaboration and innovation, the open lab and office environments incorporate AstraZeneca’s iWork philosophy, an activity-based approach that embraces industry best practices.

The University of Cambridge opened a £60 million facility for the Department of Chemical Engineering and Biotechnology in April of 2018 in the United Kingdom. Designed by BDP to promote collaboration and interaction, the 118,400-sf facility features a central atrium, BSL-2 and BSL-3 biological laboratories, cleanrooms, laser labs, optical and imaging suites, and a magnetic resonance research center.

Lonza opened a 300,000-sf cell and gene therapy manufacturing center in April of 2018 in Pearland, Texas. The facility features eight independent cGMP modular cleanrooms with single-use bioreactors and a fully segregated fill/finish suite. Supporting the development of new therapies from initial concept through the pre-clinical, clinical, and commercialization phases, the integrated building includes research labs, offices, manufacturing and production spaces, and support.

Bayer Crop Science is partnering with the University of California, Davis to create the CoLaborator facility in West Sacramento. Located in Bayer's Innovation Hub for Crop Science, the 3,000-sf facility will offer open, flexible facilities to support university-affiliated startups. Housing up to ten researchers, the project will provide equipment for the testing of agricultural and food-related innovations integrated with collaboration spaces for interaction with other entrepreneurs.

The International Society for Pharmaceutical Engineering announced the category winners for 2018 ISPE Facility of the Year Awards in March of 2018. The awards include: 

Sanofi Genzyme is expanding its presence in the Framingham Technology Park in Massachusetts where its $80 million, 72,000-sf biomanufacturing facility is currently under construction. A two-story, 14,821-sf addition to the project will enable Sanofi Genzyme to increase its production capacity for advanced therapeutics.